Quince Therapeutics, Inc. (IRLA) Free cash flow 2018–2025
Quince Therapeutics, Inc. (IRLA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$41.8MFY2025 · since FY2018: -$11.9M → -$41.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$41.8M | -29.9% |
| FY2024 | -$32.2M | -74.3% |
| FY2023 | -$18.5M | +58.2% |
| FY2022 | -$44.2M | +30.0% |
| FY2021 | -$63.1M | -24.1% |
| FY2020 | -$50.9M | -52.6% |
| FY2019 | -$33.3M | -179.9% |
| FY2018 | -$11.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More IRLA financial trends
IRLA RevenueIRLA Net incomeIRLA Net marginIRLA Gross profitIRLA Gross marginIRLA Operating incomeIRLA Operating marginIRLA Operating cash flowIRLA Capital expendituresIRLA Return on equityIRLA Stock buybacksIRLA Dividends paidIRLA Total assetsIRLA Total liabilitiesIRLA Shareholders’ equityIRLA overview →